INOD · Investment summary · as of 30 July 2026
Priced slightly ahead of what the business has demonstrated
Business type: Compounder · scaling but economically observable
The operating path required by today's price is not achievable on the evidence.
At $60.07, INOD requires a 48% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 34%.
The value rests on an exit multiple of 8.5x and a terminal operating margin of 17%. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: the single customer representing 56% of Q1 2026 revenue and 65% of gross receivables at 31 March 2026 reduces, delays or terminates its statements of work.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | Quarterly revenue $32.553m (Q2 2024) -> $52.224m (Q3 2024), from XBRL companyfacts; operating margin 0.4% FY2023 -> 14.3% FY2024 -> 15.8% FY2025 -> 18.8% Q1 2026. |
| What do we forecast? | Revenue growth of 34% demonstrated; a terminal operating margin of 17%; an exit multiple of 8.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -14.0 percentage points. |
| What is it worth? | Twelve-month target $87.90, +46% from the struck price. Scenario-weighted expected return net of costs +31.1%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| Q2 2026 10-Q (expected filing early August 2026) and Q3 2026 10-Q (expected filing early November 2026) | Revenue from the largest customer is 58% or more of total revenue in… | Neither leg of the condition opposite is met at this date | Revenue from the largest customer is 58% or more of total revenue in EITHER Q2 2026 or Q3 2026 - i.e. at or above the… |
| 6 November 2025 | Q2 2026 plus Q3 2026 revenue combined is below $180.2m - i.e. below… | Q2 2026 plus Q3 2026 revenue combined is at or above $180.2m - i.e. below flat sequential against Q1 2026's $90.096m. | Q2 2026 plus Q3 2026 revenue combined is below $180.2m - i.e. below flat sequential against Q1 2026's $90.096m. |
| FY2026, tested cumulatively at Q2 and Q3 and finally in the FY2026 10-K (expected February 2027) | The second Big Tech programme delivers less than $36m across Q2-Q4… | The second Big Tech programme delivers at least $36m across Q2-Q4 2026, against the ~$51m full-year figure announced on… | The second Big Tech programme delivers less than $36m across Q2-Q4 2026, against the ~$51m full-year figure announced… |
| Q2 2026 and Q3 2026 10-Qs | TTM gross margin falls below 39.5% - the FY2025 level - for two… | TTM gross margin falls at or above 39.5% - the FY2025 level - for two consecutive quarters, reversing the mix shift… | TTM gross margin falls below 39.5% - the FY2025 level - for two consecutive quarters, reversing the mix shift from… |
The single customer representing 56% of Q1 2026 revenue and 65% of gross receivables at 31 March 2026 reduces, delays or terminates its statements of work. It may do so on 30-90 days' notice without penalty - the 10-K states the master agreements 'generally do not obligate customers to purchase services in future periods'. There is no committed backlog and no RPO disclosure; deferred revenue is $7.154m = 2.5% of TTM revenue and falling ($7.493m at FY2025 year-end). Three mechanisms, in descending likelihood: (1) PROGRAMME COMPLETION WITHOUT REPLACEMENT - the 10-K risk factor names it verbatim, 'potential inability to replace projects that are completed, canceled or reduced'; this is the base mechanism and it has an in-house precedent, Synodex revenue fell 8% in FY2025 with the 10-K attributing it 'primarily to termination of a customer contract'.
Estimated probability 8%, against the 20% level at which the position would be resized. It sits within that level.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $87.90 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | The single customer representing 56% of Q1 2026 revenue and 65% of gross receivables at 31 March 2026 reduces, delays or terminates its statements of work. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -14.0 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is the permanent-loss mechanism: the single customer representing 56% of Q1 2026 revenue and 65% of gross receivables at 31 March 2026 reduces, delays or terminates its statements of work. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $47.36, which forces an immediate review.